NCT06508021View on ClinicalTrials.gov

A Study of Andecaliximab in Participants With Fibrodysplasia Ossificans Progressiva (FOP)

PHASE2/PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

92

Participants

Timeline

Start Date

October 25, 2024

Primary Completion Date

February 4, 2029

Study Completion Date

February 4, 2029

Conditions
Fibrodysplasia Ossificans Progressiva
Interventions
DRUG

Andecaliximab

Dose level A or B

DRUG

Placebo

Blinded

DRUG

Andecaliximab

Dose level A or B (or age adjusted dose)

Trial Locations (3)

19104

University of Pennsylvania - Perelman Center for Advanced Medicine, Philadelphia

55905

Mayo Clinic, Rochester

94143

University of California San Francisco (UCSF), San Francisco

All Listed Sponsors
lead

Ashibio Inc

INDUSTRY